In support with these observations, several preclinical studies have also shown that the blockade of hedgehog signaling pathway using an inhibitor of SMO activity, such as cyclopamine or NVP-LDE-225 (Erismodegib), reduced the proliferation, invasiveness and/or metastatic potential of PC cells, and reversed chemoresistance and prevented tumor relapse after treatment cessation in vivo [14, 49–51]. This evidence concerns the gene SMO and neoplasm.